The merger transforms CYCN from a cash-poor shell into a well-capitalized clinical-stage biotech with ~$473M pro forma cash. The extreme dilution for legacy CYCN holders (to ~1.1% ownership) is already priced in. For KRSA, the key catalyst is KRSA-028 Phase 1 data mid-2027. Monitor cash burn rate and any early pipeline updates. The CVR structure for legacy Cyclerion assets provides a small potential upside path for former CYCN holders but is highly uncertain.
Price Chart
Executive Summary
Korsana Biosciences (formerly Cyclerion Therapeutics) completed its reverse merger with Korsana on September 8, 2026, ceasing to be a shell company. Former Cyclerion shareholders now own approximately 1.1% of the combined entity, while Korsana securityholders (including $380M PIPE investors) own ~98.9%. The combined company trades under KRSA and focuses on KRSA-028, an anti-amyloid beta therapy for Alzheimer's disease, with Phase 1 data expected mid-2027. The filing includes Korsana's Q2 2026 financials showing a net loss of $17.4M and cash of $121.2M, plus pro forma combined financials projecting a combined net loss of $35.8M for H1 2026.
Key Financial Metrics
Key Facts
- Reverse merger closed September 8, 2026; Cyclerion renamed Korsana Biosciences, Inc. (ticker KRSA)
- Former Cyclerion shareholders own ~1.1% of combined company; Korsana securityholders own ~98.9%
- $380M PIPE financing closed concurrently with the merger
- Combined company has ~$473.5M pro forma cash as of June 30, 2026
- Lead candidate KRSA-028 (anti-amyloid beta) for Alzheimer's; Phase 1 data expected mid-2027
- Korsana Q2 2026 net loss $17.4M; H1 2026 net loss $30.9M; accumulated deficit $66.6M
- Pro forma combined H1 2026 net loss $35.8M; pro forma combined FY2025 net loss $40.2M
- CYCN shareholders received CVRs for legacy asset proceeds (Tisento, Akebia license)
- Board reconstituted with 6 members; Fairmount/Venrock affiliates hold ~30% combined stake
Financial Impact
Pro forma combined cash ~$473.5M; H1 2026 combined net loss ~$35.8M; $380M PIPE gross proceeds
Risk Factors
- Extreme dilution for legacy CYCN shareholders (~1.1% ownership post-merger)
- Pre-revenue clinical-stage biotech with no approved products; significant ongoing cash burn
- KRSA-028 is early-stage (pre-Phase 1); high clinical and regulatory risk
- CVR payments for legacy assets are contingent and may yield zero proceeds
- Going concern risk prior to merger; Korsana had $66.6M accumulated deficit as of June 30, 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-389318 |
| Document: d178159dex994.htm | 0001193125-26-389318 |
| Document: d178159d8k.htm | 0001193125-26-389318 |
| 8-K Data (Synthetic) | 0001193125-26-389318 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | — | awaiting T+5 | — | — |
Sep 11, 2026 6w ago | 8-K | $3.47 | awaiting T+5 | — | — |
Sep 10, 2026 6w ago | 3 | $3.47 | awaiting T+5 | — | — |
Aug 27, 2026 8w ago | 8-K | $3.99 $4.96 | ▲ +24.31% | ▲ +24.04% | — |
Aug 10, 2026 11w ago | 425 | $3.57 $4.12 | ▲ +15.41% | ▲ +15.81% | — |
Aug 3, 2026 12w ago | 425 | $3.51 $3.57 | ▲ +1.71% | ▲ +1.81% | — |
Jul 27, 2026 13w ago | EFFECT | $3.50 $3.44 | ▼ −1.71% | ▼ −2.79% | — |
Jul 10, 2026 15w ago | 425 | $3.82 $3.64 | ▼ −4.71% | ▼ −3.93% | — |
Jun 9, 2026 20w ago | S-4/A | $3.09 $3.18 | ▼ −2.91% | ▲ +0.52% | — |
Apr 30, 2026 25w ago | 10-K/A | $3.31 $3.24 | ▼ −2.11% | ▼ −3.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers